Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
Go back to Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients| Regeneron (NASDAQ: REGN) | Delayed: 815.63 -12.09 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $827.72 | 52 Week High | $592.36 | |||
| Open | $814.36 | 52 Week Low | $325.35 | |||
| Day High | $821.17 | P/E | 214.08 | |||
| Day Low | $799.42 | EPS | $3.81 | |||
| Volume | 88,920 | |||||

